Opus Genetics, Inc. (IRD)
| Market Cap | 30.94M |
| Revenue (ttm) | 8.38M |
| Net Income (ttm) | -27.19M |
| Shares Out | 31.44M |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 83,128 |
| Open | 0.980 |
| Previous Close | 0.980 |
| Day's Range | 0.970 - 1.000 |
| 52-Week Range | 0.850 - 3.400 |
| Beta | 0.32 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2024 |
About IRD
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II cl... [Read more]
News
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FARMINGTON HILLS, Mich., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherite...